CareCloud Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

CareCloud wird ein Gewinn- und Umsatzwachstum von 157.5% bzw. 5.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 157.3% pro Jahr wachsen soll.

Wichtige Informationen

157.5%

Wachstumsrate der Gewinne

157.3%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	26.9%
Wachstumsrate der Einnahmen	5.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think CareCloud (NASDAQ:CCLD) Has A Fair Chunk Of Debt

Jun 27

CareCloud, Inc. (NASDAQ:CCLD) Held Back By Insufficient Growth Even After Shares Climb 158%

May 22

CareCloud, Inc. (NASDAQ:CCLD) Shares Could Be 42% Below Their Intrinsic Value Estimate

Mar 22

The Market Doesn't Like What It Sees From CareCloud, Inc.'s (NASDAQ:CCLD) Revenues Yet As Shares Tumble 27%

Mar 22

Little Excitement Around CareCloud, Inc.'s (NASDAQ:CCLD) Revenues As Shares Take 25% Pounding

Feb 02

Is CareCloud (NASDAQ:CCLD) Using Too Much Debt?

Jan 30

CareCloud, Inc.'s (NASDAQ:CCLD) 31% Dip In Price Shows Sentiment Is Matching Revenues

Dec 19

CareCloud, Inc. (NASDAQ:CCLD) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 06

There's Been No Shortage Of Growth Recently For CareCloud's (NASDAQ:CCLD) Returns On Capital

Mar 05

CareCloud (NASDAQ:MTBC) Is Looking To Continue Growing Its Returns On Capital

Aug 20

These 4 Measures Indicate That CareCloud (NASDAQ:MTBC) Is Using Debt Safely

Jul 23

CareCloud (NASDAQ:MTBC) Shareholders Will Want The ROCE Trajectory To Continue

May 12

MTBC Has Dropped A 'Bomb' On MTBCP, Consequently Creating A 'Game-Changer' Event For Both

Jan 28

CareCloud EPS beats by $0.03, beats on revenue

May 06

MTBC (MTBC) Investor Presentation - Slideshow

Nov 19

MTBC's CareCloud inks growth-focused partnership with MDS Medical

Nov 12

MTBC EPS misses by $0.03, beats on revenue

Nov 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CCLD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	125	-1	N/A	22	4
12/31/2024	116	0	N/A	20	4
3/31/2024	113	-60	8	19	N/A
12/31/2023	117	-64	4	15	N/A
9/30/2023	121	-20	6	18	N/A
6/30/2023	126	-16	8	20	N/A
3/31/2023	133	-12	7	19	N/A
12/31/2022	139	-10	9	21	N/A
9/30/2022	144	-7	9	21	N/A
6/30/2022	148	-6	8	19	N/A
3/31/2022	145	-9	4	15	N/A
12/31/2021	140	-11	3	13	N/A
9/30/2021	134	-15	1	11	N/A
6/30/2021	128	-18	-5	4	N/A
3/31/2021	113	-23	-4	4	N/A
12/31/2020	105	-23	-9	-1	N/A
9/30/2020	89	-21	-8	-1	N/A
6/30/2020	74	-16	-4	1	N/A
3/31/2020	71	-11	-1	3	N/A
12/31/2019	64	-7	5	8	N/A
9/30/2019	65	-8	5	7	N/A
6/30/2019	65	-9	7	8	N/A
3/31/2019	57	-8	6	7	N/A
12/31/2018	51	-7	6	7	N/A
9/30/2018	42	-6	5	6	N/A
6/30/2018	33	-4	2	3	N/A
3/31/2018	32	-5	1	2	N/A
12/31/2017	32	-8	N/A	0	N/A
9/30/2017	32	-11	N/A	-2	N/A
6/30/2017	30	-11	N/A	-1	N/A
3/31/2017	28	-10	N/A	-1	N/A
12/31/2016	24	-10	N/A	-1	N/A
9/30/2016	21	-6	N/A	0	N/A
6/30/2016	21	-6	N/A	-1	N/A
3/31/2016	22	-6	N/A	-1	N/A
12/31/2015	23	-5	N/A	-2	N/A
9/30/2015	25	-5	N/A	-3	N/A
6/30/2015	25	-6	N/A	-4	N/A
3/31/2015	22	-5	N/A	-4	N/A
12/31/2014	18	-5	N/A	-3	N/A
9/30/2014	14	-3	N/A	-2	N/A
6/30/2014	11	-1	N/A	1	N/A
3/31/2014	11	-1	N/A	1	N/A
12/31/2013	10	0	N/A	1	N/A
9/30/2013	10	0	N/A	1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CCLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CCLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CCLD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CCLDDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CCLDDie Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CCLD in 3 Jahren voraussichtlich hoch sein wird

CareCloud Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.037 loss

Price target increased by 7.3% to US$3.68

CareCloud, Inc. Reiterates Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

CareCloud, Inc. Reiterates Revenue Guidance for the Fiscal Year Ending December 31, 2023

Carecloud, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Recent updates

We Think CareCloud (NASDAQ:CCLD) Has A Fair Chunk Of Debt

CareCloud, Inc. (NASDAQ:CCLD) Held Back By Insufficient Growth Even After Shares Climb 158%

CareCloud, Inc Promotes Crystal Williams to Chief Operating Officer

Consensus EPS estimates upgraded to US$0.037 loss

Price target increased by 7.3% to US$3.68

CareCloud, Inc. Reiterates Revenue Guidance for the Year 2024

CareCloud, Inc. to Report Q1, 2024 Results on May 14, 2024

CareCloud, Inc., Annual General Meeting, Jun 17, 2024

Consensus EPS estimates upgraded to US$0.77 loss, revenue downgraded

CareCloud, Inc. (NASDAQ:CCLD) Shares Could Be 42% Below Their Intrinsic Value Estimate

The Market Doesn't Like What It Sees From CareCloud, Inc.'s (NASDAQ:CCLD) Revenues Yet As Shares Tumble 27%

Full year 2023 earnings released: US$4.11 loss per share (vs US$0.67 loss in FY 2022)

CareCloud, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Little Excitement Around CareCloud, Inc.'s (NASDAQ:CCLD) Revenues As Shares Take 25% Pounding

Is CareCloud (NASDAQ:CCLD) Using Too Much Debt?

CareCloud, Inc. Announces Chief Financial Officer Changes

CareCloud Takes Center Stage at The Arab Health Exhibition and Congress 2024

Founder & Executive Chairman recently bought US$645k worth of stock

CareCloud, Inc.'s (NASDAQ:CCLD) 31% Dip In Price Shows Sentiment Is Matching Revenues

Carecloud, Inc. Appoints Justin Pierce as Its Chief Sales Officer

Independent Director recently bought US$97k worth of stock

CareCloud, Inc. Reiterates Revenue Guidance for the Fiscal Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

CareCloud, Inc. to Report Q3, 2023 Results on Nov 02, 2023

CareCloud, Inc. Appoints Bill Korn as Board of Directors

Is CareCloud (NASDAQ:CCLD) A Risky Investment?

Carecloud, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Things Look Grim For CareCloud, Inc. (NASDAQ:CCLD) After Today's Downgrade

Price target decreased by 32% to US$6.28

CareCloud, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping CareCloud, Inc.'s (NASDAQ:CCLD) Muted Revenues

CareCloud, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CareCloud, Inc. Appoints Larry Steenvoorden as Chief Financial Officer

No longer forecast to breakeven

CareCloud Strengthens Leadership Team with Key Transitions

CareCloud, Inc. (NASDAQ:CCLD) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Carecloud, Inc. Reiterates Revenue Guidance for the Fiscal Year Ending December 31, 2023

There's Been No Shortage Of Growth Recently For CareCloud's (NASDAQ:CCLD) Returns On Capital

Full year 2022 earnings: EPS misses analyst expectations

CareCloud, Inc. to Report Q4, 2022 Results on Mar 02, 2023

CareCloud, Inc. to Unveil Innovative EHR Therapy Platform At American Physical Therapy Association Meeting

CareCloud, Inc. Charts Now Certified for Interoperability According to ONC Standards

CareCloud, Inc. Updates Revenue Guidance for the Year 2022 and 2023

Forecast to breakeven in 2025

Price target decreased to US$8.92

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CareCloud, Inc. Reiterates Earnings Guidance for the Year 2022

CareCloud, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CareCloud, Inc. Announces the Launch of Its Remote Patient Monitoring Solution

CareCloud, Inc. Deploys Its CareCloud Wellness to Bring Providers Next Generation Chronic Care Management Services

CareCloud (NASDAQ:MTBC) Is Looking To Continue Growing Its Returns On Capital

Consensus EPS estimates fall by 12%

Second quarter 2022 earnings: EPS exceeds analyst expectations

CareCloud, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$12.58

CareCloud, Inc. to Report Q2, 2022 Results on Aug 04, 2022

These 4 Measures Indicate That CareCloud (NASDAQ:MTBC) Is Using Debt Safely

Insufficient new directors

CareCloud (NASDAQ:MTBC) Shareholders Will Want The ROCE Trajectory To Continue

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

CareCloud, Inc. Reiterates Forward-Looking Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

CareCloud Adds Chronic Care Management Service to its Digital Health Portfolio

No longer forecast to breakeven